The next frontier in understanding biology isn't about reading more DNA. It's about reading proteins directly, at scale, and without the chemical baggage that can obscure the signal. That's the procurement problem Pumpkinseed is built to solve, with a $20 million Series A check from NfX and Future Ventures as its initial budget [GenomeWeb]. The Palo Alto startup's bet is a silicon photonics chip platform that uses Raman spectroscopy and machine learning to sequence proteins label-free, a technical path that, if it works at commercial volumes, could change how drug discovery and diagnostics are done.
The wedge is optical, not biochemical
Most protein analysis today relies on indirect methods, mass spectrometry, or fluorescent labeling,processes that can be slow, expensive, and sometimes alter the very molecules they're trying to measure. Pumpkinseed's core concept, called deSIPHR, sidesteps this by aiming for high-resolution, single-molecule sequencing without labels or amplification [PERPLEXITY SONAR PRO BRIEF]. The proposed workflow is methodical: a protein is immobilized, its terminal amino acid is cleaved, and a Raman spectrum of the resulting peptide is captured. This cycle repeats, stepwise, with machine learning stitching the spectral snapshots back into the original protein sequence. The differentiator isn't a novel biochemical step; it's the marriage of custom biochemistry to a scalable, silicon photonics-based optical detection system. The company uses nanophotonic simulations, via a partnership with Flexcompute's Tidy3D, to design the optical structures on its chips [Tidy3D Case Studies, 2026]. The goal is industrial scale: building billions of sensors across a silicon wafer to turn proteins into readable signals at volume [Nhat Vu - LinkedIn, 2026].
A Stanford-rooted team with deep photonics expertise
The founding team's credentials lean heavily into the photonics and materials science required to make this bet. Co-founder Jennifer Dionne is a professor of materials science and radiology at Stanford, with a research focus on nanophotonics for biological sensing [Jennifer Dionne, 2026]. This isn't an academic side project; her work is directly applicable to the chip design. Jack Hu, listed as co-founder and Chief Scientific Officer, and Nhat Vu, co-founder and CTO, round out the technical leadership [Stanford U Spinout Pumpkinseed, 2026]. The early team is small, estimated at 2-10 employees, with recent hires focusing on senior research scientist roles [LinkedIn] [MyVisaJobs, 2026]. For a hardware-heavy deeptech play, this composition makes sense,the initial capital is going into R&D and chip development, not a large commercial organization.
The funding and the path to a first customer
The $20 million Series A, co-led by NfX and Future Ventures with participation from Base4 and AdVentures, is a significant vote of confidence in a pre-revenue, pre-product company [GenomeWeb]. The round size suggests investors are buying into the long hardware development and validation cycle inherent in building a new sequencing platform. Traction, so far, is technical. Public disclosures point to research collaborations and simulation partnerships, like the one with Tidy3D, rather than named pharmaceutical or diagnostic customers. The next twelve months will be critical for transitioning from technical validation to a tangible product roadmap and, ultimately, a first commercial partnership. The ideal customer profile here is clear, but landing it is the hard part.
The realistic buyer is a translational research group within a large biopharma company or a specialized diagnostics developer. They are budget owners for early-stage R&D tools, tasked with finding new biomarkers or understanding protein-drug interactions with higher fidelity. Their procurement cycle is long and risk-averse, but they have a clear pain point: current proteomics methods are often too slow, too expensive, or too indirect for the questions they need to answer. Pumpkinseed is not selling to academic labs browsing catalogs; it's selling to enterprise R&D units that can commit to a platform.
Where the wheels could come off
The ambition is matched by a formidable set of technical and commercial risks. The field of next-generation protein sequencing is crowded with well-funded competitors, each with a different technical approach. Pumpkinseed's success hinges on executing a complex multi-disciplinary integration,biochemistry, photonics, and machine learning,at a cost and reliability that can compete with established and emerging alternatives.
- Technical integration risk. The promise rests on making Raman spectroscopy sensitive enough at the single-molecule level and marrying it reliably with a stepwise cleavage chemistry. Any drift in either process corrupts the sequence reconstruction.
- Time-to-data risk. Even if the technology works, the speed of analysis matters. If the cyclic cleavage and read process is too slow for the throughput demands of drug discovery, it becomes a niche research tool.
- Commercial scaling risk. Building nanophotonic chips is one challenge; manufacturing them consistently at low cost and integrating them into a benchtop instrument that life scientists can operate is another entirely.
The competitive set is already active, with companies like Nautilus Biotechnology, Quantum-Si, and Encodia pursuing their own versions of next-gen protein analysis. Pumpkinseed's answer is its optical, label-free wedge. The company will need to demonstrate not just that its method works, but that it works with a clear advantage in simplicity, cost, or data quality over these incumbents. The renewal motion for a capital equipment sale in this space is unforgiving; the first instrument placement must lead to consumable sales and repeat orders.
What to watch in the next 12 months
The milestones for Pumpkinseed are less about headcount growth and more about technical and commercial proofs. A successful beta test of a prototype chip with an external research partner would be a strong signal. So would a disclosed collaboration with a pharma company, even if non-exclusive. The hiring roadmap may also indicate priorities; openings for roles like computational biologists or instrument engineers would signal a move toward productization [Jennifer Dionne on LinkedIn, 2026]. Given the Series A round, another fundraising event is unlikely in the immediate future, but progress against these technical milestones will dictate the timing and size of a Series B.
The realistic competitive set extends beyond pure-play sequencers. In the near term, Pumpkinseed is also competing against the inertia of existing mass spectrometry workflows and the ecosystem built around them. Its initial beachhead likely isn't displacing a core pathology lab tool, but rather capturing new, exploratory applications where label-free, de novo sequencing provides unique value. For the procurement officer evaluating this, the question isn't just about the technology's elegance, but about the total cost and reliability of the data over a five-year instrument lifecycle. That's the benchmark Pumpkinseed's chips will ultimately be measured against.
Sources
- [GenomeWeb] Stanford University Spinout Pumpkinseed Raises $20M to Advance Protein Sequencing Tech | https://www.genomeweb.com/business-news/stanford-university-spinout-pumpkinseed-raises-20m-advance-protein-sequencing-tech
- [PERPLEXITY SONAR PRO BRIEF] PERPLEXITY SONAR PRO BRIEF
- [Tidy3D Case Studies, 2026] Pumpkinseed's Protein Sequencing Innovation with Tidy3D's Nanophotonic Simulations | https://www.flexcompute.com/blog/2024/09/10/pumpkinseed-s-protein-sequencing-innovation-with-tidy3d-s-nanophotonic-simulations/
- [Nhat Vu - LinkedIn, 2026] Nhat Vu - Menlo Park, California, United States | Professional Profile | LinkedIn
- [Jennifer Dionne, 2026] Jennifer Dionne - Stanford Materials Science and Engineering
- [Stanford U Spinout Pumpkinseed, 2026] Stanford U Spinout Pumpkinseed Pursues Chip-Based Peptide Sequencing, Immune Cell Analysis | GenomeWeb
- [LinkedIn] LinkedIn Company Profile
- [MyVisaJobs, 2026] MyVisaJobs Data
- [Jennifer Dionne on LinkedIn, 2026] Jennifer Dionne on LinkedIn: Dear chemistry friends - don't let your work Bohr you! Pumpkinseed is…